Latest Listings And Ipos News

Imagion Biosystems reported a $1.66 million loss for the half-year ending June 2025 while progressing its MagSense® HER2 Imaging Agent towards a Phase 2 FDA trial and securing $3.5 million in new funding.

Infragreen Group Ltd has reported a strong FY25 performance, exceeding its prospectus forecasts post-IPO and advancing its footprint in clean energy and waste recovery sectors. The company’s strategic acquisitions and organic growth set the stage for continued momentum into FY26.

Infragreen Group Limited has reported a robust FY25 performance, with pro forma revenue and EBITDA significantly exceeding forecasts, supported by a successful $40 million IPO.

Infragreen Group Limited reported a robust 190% increase in revenue for FY25 following its successful IPO, despite a significant statutory net loss. The company’s strategic acquisitions and expanded ownership stakes underpin a promising outlook in sustainable infrastructure.

SIV Capital Limited reported a statutory loss of $112,789 for the year ended June 2025, continuing its operational scale-down with only four active rental contracts. The company remains debt-free with $8.18 million in cash but its ASX securities remain suspended as it evaluates a confidential corporate opportunity.

James Hardie Industries confirms its Q1 FY26 earnings met market expectations despite a challenging North American housing market, while revising its FY26 guidance following the AZEK acquisition.

US Masters Residential Property Group reports a half-year profit and advances its ambitious asset sales program, while navigating a significant US tax structure change and mixed market conditions.

H&G High Conviction Limited reported a $2.9 million net loss for FY2025 amid challenging market conditions and completed a major asset sale to Hancock & Gore Limited, marking a pivotal shift in its business model.

AXP Energy has updated its resource disclosures and is accelerating its gas-to-power strategy to fuel bitcoin mining operations in Oklahoma, leveraging proven oil fields and strong industry partnerships.

Cambium Bio has updated its placement, raising A$2.17 million to fund late-stage clinical trials for its lead ophthalmology product, Elate Ocular®. The capital raise reflects strong investor interest and strategic backing.

Pengana International Equities has acknowledged breaching ASX disclosure rules by sharing details of a new private credit strategy with media before official announcement, prompting a policy overhaul.

WAM Research Limited reported a robust 22.4% increase in its investment portfolio for FY2025, significantly outperforming key ASX indices, while maintaining a high dividend yield of 8.1%.